Podcasts about comparator

Kan, Kanama ve Transfüzyon İlk başarılı kan transfüzyonu yaklaşık olarak 250 yıl önce yapılmıştır ve artık bu uygulama, modern tıbbın bir köşe taşı haline gelmiştir. Günümüzde, hayatı tehdit edici kanama, cerrahi kanama başta olmak üzere birçok endikasyonla yaygın olarak kullanılmaktadır. ABD verilerine göre yılda 16 milyondan fazla ünite kan ürünü transfüzyonu yapılmaktadır. Kan ürünleri, zor elde edilen kıt bir kaynaktır dolayısı ile israf edilmemelidir. Klinisyenlerin hastalara kan verme sıklığına rağmen, transfüzyon kurallarına bağlılık, kan israfını önleme stratejileri ve acil durumlarda kan ve kan yardımcı maddelerine yönelik tedavi algoritmaları da dahil olmak üzere pek çok bilinmeyen vardır. Bu konulara yönelik olarak geçtiğimiz aylarda JAMA'da (Journal of the American Medical Association) eritrosit transfüzyonu hakkında bir klinik kılavuz​1​ ve bununla ilişkili editoryal yazılar​2,3​ yayınlandı. Bu yazıların esas amacı; yaygın olarak kullanılan birçok yararının yanı sıra zararları da olabilecek eritrosit transfüzyonu hakkında önerilerde bulunmaktı. Biz de bu yazıları inceleyeceğiz. İyi okumalar. Eritrosit Transfüzyonu-2023 AABB (Association fort he Advancement of Blood & Biotherapies) Uluslararası Kılavuzu Eritrosit transfüzyonu yaygın uygulanan ve pahalı bir işlemdir. Dünya genelinde ortalama olarak yılda 118 milyon ünite eritrosit elde edilmektedir. ABD'de ortalama 1 ünite eritrositin maliyeti 215$'dır ve bu fiyat ülkeden ülkeye değişmektedir. Ayrıca bu fiyata dağıtım, depolama, işleme, uygulama ve komplikasyon gözlemleme ücretleri dahil değildir. Birçok transfüzyon merkezi, yeterli miktarda eritrosit stokunu koruma konusunda, COVID-19 salgınının daha da kötüleştirdiği zorluklarla karşı karşıyadır. Klinisyenler hastalara yalnızca yararların zararlardan ağır bastığı durumlarda eritrosit transfüzyonu önermelidir. Zararlar enfeksiyöz ve enfeksiyöz olmayan komplikasyonları içerir; ciddi reaksiyonlar nadir olmasına rağmen ciddi zarar potansiyeli içermektedir (Tablo 1). Bu yüzden kesin fayda sağlamayacak transfüzyonlardan kaçınılması hastayı korumak açısından önerilmektedir. Yan etkiEritrosit transfüzyonu başına yaklaşık riskFebril reaksiyon1:161Alerjik reaksiyon1:345Transfüzyon ilişkili dolaşım yüklenmesi1:125Transfüzyon ilişkili akut akciğer hasarı (TRALI)1:1250Anafilaktik reaksiyon1:5000Hepatit B virüsü1:1 100 000Hepatit C virüsü1:1 200 000HIV1:1 600 000 Tablo 1: ABD'de Eritrosit Transfüzyonu için Birim Başına Yaklaşık Risk ​4,5​ PICO (Population, Intervention, Comparator, ve Outcomes) Soruları Çalışmada temel olarak iki PICO sorusuna öneride bulunulmuştur. Hastanede yatan, hemodinamik olarak stabil yetişkin hastalar için, klinisyenler kısıtlayıcı bir strateji (tipik hemoglobin düzeyi

Gross Margin Is the Comparator Hello, this is Hall T. Martin with the Startup Funding Espresso -- your daily shot of startup funding and investing. Since not all revenue is the same, how does an investor compare one company to another? Gross margin is one key comparator. It measures how much revenue is available to invest in the growth of the business. Gross profit is calculated by taking revenue minus the cost of goods sold. Gross margin is calculated by taking gross profit divided by revenue. The higher the gross margin the more capital efficient the business. This means the company can go further with less funding. Companies vary in their gross margin. Some have very efficient product delivery models while others have high-cost models. While not all revenue is the same, gross margin predicts funds available for future growth.  Consider the gross margin in your investment analysis of a business.   Thank you for joining us for the Startup Funding Espresso where we help startups and investors connect for funding. Let's go startup something today. _______________________________________________________ For more episodes from Investor Connect, please visit the site at:   Check out our other podcasts here:   For Investors check out:   For Startups check out:   For eGuides check out:   For upcoming Events, check out    For Feedback please contact info@tencapital.group    Please , share, and leave a review. Music courtesy of .

In this episode, Sarah interviews Dr. Gillian Woollett, VP, Head of Regulatory Strategy and Policy at Samsung Bioepis, about the challenges of bring biosimilars to market. Dr. Woollett clears up some common misconceptions about achieving interchangeable status and addresses the issues with differences in global regulatory standards for biologics medicines. Sarah and Dr. Woollett also discuss Samsung Bioepis' first US Biosimilar Market Report (linked below) and some of its key findings on biosimilar cost savings, uptake and market share. She also shares the way forward to help biosimilars see broader use both in the US and Europe.Read about the publications mentioned in this episode here:Samsung Bioepis' First US Biosimilar Market ReportA 'Global Reference' Comparator for Biosimilar DevelopmentAn Efficient Development Paradigm for BiosimilarsComparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized RelianceInterchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical OneThe Role of PD Biomarkers in Biosimilar Development - To Get the Right Answer One Must First Ask the Right QuestionFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featuredSocial Post:

MEP EP#360: Current Conscience ComparatorFramework, Noctua, and other brands add official 3D models to Printables Prusa Research's “Printables” website added a new section called “Brands” Manufacturers and OEMs can upload verified models for their products CNC Update All of the fasteners arrive this week along with the aluminum extrusions Build weekend Developed a 3d printable cable tie for 4040 t-slots 3d prints with planned bending sections Other than iteration and experience is there a way to design this? Elastic deformation in the area that we want - avoid plastic deformation on stress-strain curve Will be printing along with the spray system from episode 354 The Return of the Cat Feeder Unreminder MAX9019 Comparator Oscillator Low power design considerations Consider every current path for leakage current Super Capacitor Leakage Comparison DSF505Q6R0JBG 5F at 6VDC 40uA leakage HSL0814-3R8106-R 10F at 3.8VDC 2.0-3.0uA leakage Get the timer working LTC2956-1 0.8uA Use the enable output to switch between what segments are being driven on the TN LCD DG419 signal switcher

Dr. Rebecca Price (University of Pittsburgh) discusses a novel, computer-based intervention designed to extend the antidepressant effects of a single dose of ketamine. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin discusses the rest of the December issue and what draws it together. Price interview [00:40] What does the computer-based intervention consist of? [03:55] Comparator arms [05:25] Are there immediate clinical implications? [08:04] Limitations [10:19] Further research [12:17] Kalin interview [14:02] Price et al. [14:28] Santos et al. [17:28] Grilo et al. [19:43] Solmi et al.v [22:51] Lam et al. [25:01] Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Stitcher, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse articles online. How authors may submit their work. Follow the journals of APA Publishing on Twitter. E-mail us at ajp@psych.org

Have you heard of the Gospel of Thomas? What about the Gospel of Philip or Judas? Although most Christians are only familiar with the four Gospels contained in the Bible, ancient Christians wrote quite a few other Gospels as well. How do we know which Gospels are to be trusted? My guest today is Dr. Simon Gathercole, professor of New Testament and early Christianity at the University of Cambridge. His new book, The Gospel and the Gospels, puts forward a commonsense historical methodology to determine which Gospels are most reliable. Listen to this episode on Spotify or Apple Podcasts https://www.youtube.com/watch?v=RsGhQVsPdvs —— Links —— Get your copy of The Gospel and the Gospels from Eerdmans or on Amazon More about Simon Gathercole here. See also my interview with Aaron Shelenberger: Episode 444 Resurrection Objection 1: Unreliable Gospels? More podcasts on apologetics here Support Restitutio by donating here Designate Restitutio as your charity of choice for Amazon purchases Join our Restitutio Facebook Group and follow Sean Finnegan on Twitter @RestitutioSF Leave a voice message via SpeakPipe with questions or comments and we may play them out on the air Intro music: Good Vibes by MBB Attribution-ShareAlike 3.0 Unported (CC BY-SA 3.0) Free Download / Stream: Music promoted by Audio Library. Who is Sean Finnegan?  Read his bio here —— Interview Questions —— Dr. Gathercole is professor of NT and early Christianity at the University of Cambridge. He's got degrees from Cambridge and Durham university, where he studied under James Dunn. Before we jump into the book, what was that like studying under Dunn?Well, today, we're talking about your book The Gospel in the Gospels. Writing this book must have been a monumental task. It's 576 pages, hundreds of footnotes, published by Eerdmans, how long were you working on this project? Share a little about the process.Many don't know there were other Gospels that didn't make it into the New Testament. Outside of Matthew, Mark, Luke, and John, what other Gospels are there? What are they like?How can someone access these other Gospels? Would you recommend the Lost Scriptures by Bart Ehrman or The Complete Gospels by Robert Miller? or your own volume?You've done a lot of work on non-canonical Gospels over the years. What drew you to them? What about them makes them worth studying?Some say the four canonical Gospels--Matthew, Mark, Luke, and John--are not special or authoritative, but merely the ones favored by one group of Christians who managed to seize power and suppress all others. How common is this belief in the academy today? What is the central thesis of your book?How have others made the case that the canonical Gospels are best? (1 early composition, 2 massive popularity, 3 literary type of ancient biography, 4 attractiveness of worldview)You focused on theological content. You talk a lot about the kerygma as the comparator (or measuring stick against which each of the Gospels should be evaluated). What is the kerygma?What are the elements of the kerygma? (1 Jesus as Christ, 2 vicarious death, 3 resurrection, 4 crucifixion and resurrection as fulfillment of scripture). Why not include Jesus healing people or other events like his Triumphal Entry into Jerusalem?Let's go through each of these briefly. What did you find with respect to Jesus as the Christ? When you compared the canonical vs. non-canonical gospels?Now, the other Gospels, the non-canonical ones, do not have all four of these components. Why do you think that is? What do you think motivated them to edit or silence these elements of the kerygma?Let's talk briefly about the charge sometimes leveled against John as untrustworthy because it's later or too theological or whatever. How does John fare in comparison to the synoptics?How has your work on this been received in the academy so far?What do you hope to see in the future?Thanks for taking the time to talk with me today. Where can people go to find out more about you and the book?

CME credits: 1.50 Valid until: 25-04-2023 Claim your CME credit at https://reachmd.com/programs/cme/multicenter-randomized-active-comparator-controlled-double-blind-double-dummy-parallel-group-dose-finding-phase-2-study-comparing-the-safety-of-the-oral-fxia-inhibitor-asundexian-with-apixaban-in-patients-with-atrial-fibrillation-pacific-af/14053/ tbd

In part 2 of episode 10, Kyle takes us through the rest of his trip to EMS. He then talks to Jon Nensen aka The Human Comparator who is behind the TTSH Arp 2600 clone, 73-75 Serge panels, Buchla USA 100 Series reissues, and some upcoming Buchla ecosystem modules of his own design. It was a great chat!Show notes:Hello: 0:00EMS Day 4: 11:30EMS Day 5 & 6: 23:15EMS Day 7: 35:35Jon Nensen Interview: 56:00Goodbye: 2:16:00For more information about Jon's projects, visit: http://www.thehumancomparator.net/Listen and subscribe to Podular Modcast: https://podularmodcast.fireside.fm/Listen and subscribe to Esoteric Modulation: https://www.esotericmodulation.com/subscribe-to-podcastSubscribe to Waveform Magazine: https://www.waveformmagazine.com/Support the show and get access to exclusive videos and audio content through Patreon: https://www.patreon.com/sourceofuncertaintyFind us on Instagram @sourceofuncertainty Visit our website and contact us at: sourceofuncertainty.audio

Manual therapy (MT) comes in all shapes and sizes - mobilisation, manipulation, mobilisation with movement, soft tissue massage, instrument assisted massage, muscle energy techniques, pointy elbows pressed into flesh and more. Patients (often) love it, and it's a popular treatment modality with therapists. Debate rages, and myths and misconceptions surround MT. Could the time we spend performing MT be better spent elsewhere? How does MT work? Is it worth using if treatment effects are short lived? Is it just used as revenue raising by therapists, while creating reliance on passive therapies? Is MT evidence-based? Is it worth including in our treatment? Which patients may benefit from MT, and which patients you should steer away from MT? In this podcast, clinical researcher, physical therapist and Professor at Duke University, Dr Chad Cook, we discuss the evidence around MT, myths and misconceptions, how MT works, and using your clinical reasoning to decide when and how to utilise MT. You'll discover: What are the arguments against manual therapy? Do the arguments against MT have merit? Does MT break up scar tissue or adhesions, correct alignment of joints, or put them back into place? Do we have evidence that MT creates reliance on passive therapies? Evidence for and against MT How to use clinical reasoning with MT How MT works - potential mechanisms What MT is NOT doing How to explain MT to your patients Clinical reasoning Identifying pain adaptive and non pain adaptive patients How MT can help identify patients with a better or worse prognosis How many sessions of MT should patients receive? How to select MT techniques Does MT cause harm and patient reliance? How to identify patient treatment expectations How to help change patient expectations Links associated with this episode: Download and subscribe to the podcast on iTunes Listen to the podcast on Spotify Improve your confidence and plantar fasciopathy results with a free trial Clinical Edge membership, and get access to the 3 part webinar series on PHP with Henrik Riel Let David know what you liked about this podcast on Twitter Review the podcast on iTunes Like the podcast on Facebook Infographics by Clinical Edge Dr Chad Cook at Duke University Twitter - @ChadCookPT Book - Orthopaedic Manual Therapy Articles associated with this episode: Bialosky et al. 2009. The Mechanisms of Manual Therapy in the Treatment of Musculoskeletal Pain: A Comprehensive Model. Bialosky JE, Bishop MD, Penza CW. Placebo mechanisms of manual therapy: a sheep in wolf's clothing?. journal of orthopaedic & sports physical therapy. 2017 May;47(5):301-4. Cook et al. 2014. Is there preliminary value to a within- and/or between-session change for determining short-term outcomes of manual therapy on mechanical neck pain? Cook et al. 2013. Early use of thrust manipulation versus non-thrust manipulation: a randomized clinical trial. Cook et al. 2012. Can a within/between-session change in pain during reassessment predict outcome using a manual therapy intervention in patients with mechanical low back pain? Cook. 2011. Immediate effects from manual therapy: much ado about nothing? Deyle et al. 2005. Physical therapy treatment effectiveness for osteoarthritis of the knee: a randomized comparison of supervised clinical exercise and manual therapy procedures versus a home exercise program. Goss et al. 2004. A Cochrane review of manipulation and mobilization for mechanical neck disorders. Learmann et al. 2014. No Differences in Outcomes in People with Low Back Pain Who Met the Clinical Prediction Rule for Lumbar Spine Manipulation When a Pragmatic Non-thrust Manipulation Was Used as the Comparator. Rubinstein et al. 2011. Spinal manipulation therapy for chronic low back pain. Schneider et al. 2014. Derivation of a clinical decision guide in the diagnosis of cervical facet joint pain. Traeger et al. 2018. Effect of Intensive Patient Education vs Placebo Patient Education on Outcomes in Patients With Acute Low Back Pain.

I spoke with Owen Byrd, the Chief Evangelist and General Counsel of Lex Machina, a company that provides legal analytics to enable lawyers to make data-driven decisions. We discussed how lawyers are currently using analytics to make decisions, Lex Machina’s evolution since its acquisition by LexisNexis, the connection between IP and securities analytics, the company’s new Comparator apps, and where the legal industry is headed, among other topics.

I spoke with Owen Byrd, the Chief Evangelist and General Counsel of Lex Machina, a company that provides legal analytics to enable lawyers to make data-driven decisions. We discussed how lawyers are currently using analytics to make decisions, Lex Machina's evolution since its acquisition by LexisNexis, the connection between IP and securities analytics, the company's new Comparator apps, and where the legal industry is headed, among other topics.

I spoke with Owen Byrd, the Chief Evangelist and General Counsel of Lex Machina, a company that provides legal analytics to enable lawyers to make data-driven decisions. We discussed how lawyers are currently using analytics to make decisions, Lex Machina’s evolution since its acquisition by LexisNexis, the connection between IP and securities analytics, the company’s new Comparator apps, and where the legal industry is headed, among other topics.

I spoke with Owen Byrd, the Chief Evangelist and General Counsel of Lex Machina, a company that provides legal analytics to enable lawyers to make data-driven decisions. We discussed how lawyers are currently using analytics to make decisions, Lex Machina’s evolution since its acquisition by LexisNexis, the connection between IP and securities analytics, the company’s new Comparator apps, and where the legal industry is headed, among other topics.

Justice Kevin Bell, Justice of the Supreme Court of Victoria - 16 October 2012. 2012-10-16.

Sourcing comparator drugs for trials is a complex ‘art’ that requires knowledge of trading, regional regulations and an awareness of drugmakers’ competitive concerns according to Clinigen Group CEO Peter George.

Here is a customized World for Gridworld where the message on the top is updated to show how many bugs there are and the location of the furthest Bug in the grid. You need to implement the Comparator interface for the grid world Bug class. You need to define a compare method that returns an int. Get the location of each Bug and use the compareTo method of Location. Here is the starter code: apcs.mathorama.com mpeg4 movieQuicktime movie

Date Posted: 9/30/2010Size: 7.93MBLength: 00:17:19Thought Leader: Dr. Philippe Muller, Managing Director Manufacturing and Comparator Services, Fisher Clinical ServicesIn this episode, we'll discuss using comparator drugs in clinical trials, and overcoming the issues and challenges of using comparators.Play PodcastDownload related whitepaperFor more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.

(click for podcast)Wouldn't it be FUN to have a plastic pal - your very own robot - well you CAN!Of course... not all robots are fun...Here's Marvin, everyone's favorite paranoid android, with genuine people personality!http://www.boingboing.net/2007/10/19/boing-boing-tv-tanks.htmlhttps://secure.wikimedia.org/wikipedia/en/wiki/BEAM_roboticsBEAM roboticsThe word "beam" in BEAM robotics is an acronym for Biology, Electronics, Aesthetics, and Mechanics. This is a term that refers to a style of robotics that primarily uses simple analog circuits, such as comparators, instead of a microprocessor in order to produce an unusually simple design (in comparison to traditional mobile robots) that trades flexibility for robustness and efficiency in performing the task for which it was designed. ...he basic BEAM principles focus on a stimulus-response based ability within a machine. The underlying mechanism was invented by Mark W. Tilden where the circuit (or a Nv net of Nv neurons) is used to simulate biological neuron behaviors. ... Other rules that are included (and to varying degrees applied): Use the lowest number possible of electronic elements ("keep it simple")Recycle and reuse technoscrapUse radiant energy (such as solar power)http://www.streettech.com/modules.php?op=modload&name=News&file=article&sid=1618Boing Boing tv: Tanks-A-Lot / Mark's Vibrobot Posted by Xeni Jardin, October 19, 2007 10:21 AM | permalink http://www.boingboing.net/2007/01/15/howto-make-a-vibrobo.htmlhttp://boingboing.net/videos/vibrobot.movPROMO: http://www.spacecasey.com/Music:Title: I played my concertina Performer: Arthur Osmond.